Screen and Treat Implementation for HAT Control

Launched by INSTITUTE OF TROPICAL MEDICINE, BELGIUM · Nov 30, 2022

Keywords

ClinConnect Summary

In this study, all gHAT suspects that attend participating health facilities with suggestive symptoms and test positive in an antibody detection rapid test, will presumptively be treated with fexinidazole. Blood samples will be collected for the post-hoc confirmation of the infection. Nine Health facilities have been selected in the health zones of Kasongo, Kibombo, Kunda and Samba (province of Maniema), Kongolo (province of Tanganyika) and Lubao (province of Lomami) by the PNLTHA, and ITM, based on both epidemiological data and operational considerations.

All patients that consult the sel...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Show any suggestive symptoms of gHAT, such as headache (\>14 days), long-term fever unless other obvious cause(s), malaise, weakness, arthralgia, facial edema, pruritus, lymphadenopathy, weight loss, mental confussion, abnormal behavior, logorrhea, speech impairment, anxiety, tremor, motor weakness, ataxia, abnormal gait, abnormal movements or seizures;
• • Being older than 6 years old and weighing at least 20 kg;
• • Willing and able to provide written informed consent (assent for minors);
• • Minors (6 to 17 years old) willing and able to provide a written assent, after obtaining written informed consent from their parents.
• Exclusion Criteria:
• • Being younger than 6 years old or weighing less than 20 kg;
• • Refusal to provide informed consent;
• • Previously treated for HAT (questionnaire to patients and/or family members);
• • Pregnant women.